Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul (Apr 2008)
COMPARISON OF SERUM LEVELS OF CD26 AND CD30 IN CHRONIC RENAL FAILURE AND HEMODIALYTIC PATIENTS
Abstract
BACKGROUND AND OBJECTIVE: Various abnormalities of the immune system have been demonstrated in patients on hemodialysis. Imbalances in Th1 and Th2 responses have an important role in these complications. These cells produce predominantly some cytokine profiles and also express preferentially co-stimulatory CD26 and CD30 molecules. The aim of the present study was to determine the levels of soluble CD26 and CD30 co-stimulatory molecules in sera of chronic renal failure (CRF) and hemodialytic patients (HD). METHODS: This case-control study was performed on 60 CRF patients (30 patients with CRF and 30 end-stage renal diseases under hemodialysis) and 60 healthy individuals. Renal function was evaluated by measuring serum levels of creatinine, albumin and urea. The serum levels of soluble CD26 and CD30 were determined by a sandwich enzyme-linked immunosorbent assay. FINDINGS: The serum levels of CD26 in the HD, CRF patients, and healthy controls were 275.4±125.6, 402.9± 103.1, and 389.2±117 ng/ml, respectively. The levels of CD26 was significantly decreased in the HD group compared to the CRF and control groups (p=0.002). On the other hand, the serum levels of CD30 in the HD, CRF patients, and healthy controls were 45.3±13.7, 38.9±14.5, 20.7±10.5 U/ml, respectively. The CD30 levels were significantly higher in HD and CRF patients than controls (p<0.0001). There was no significant difference between HD and CRF groups (p=0.05). CONCLUSION: High serum levels of CD30 in line with low expression of CD26 indicate a Th2 polarization in immune responses of HD patients. It is possible that this Th2- dominated immune response may contribute to the abnormality of the immune system in HD patients.
